HomeREGULATORY
REGULATORY

Optimal Use Guidelines Issued for Opdivo, Keytruda for Melanoma, NSCLC Use
(Feb.15.2017)

The Ministry of Health, Labor and Welfare (MHLW) on February 14 issued “optimal use promotion guidelines” for the anti-PD-1 antibodies Opdivo (nivolumab) and Keytruda (pembrolizumab) for the treatment of melanoma and non-small cell lung cancer (NSCLC) ...
(LOG IN FOR FULL STORY)

News Calendar